European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
Alexander Stratigos(National and Kapodistrian University of Athens), Jean-Jacques Grob(Aix-Marseille Université), Nicole W.J. Kelleners-Smeets(Maastricht University Medical Centre), Véronique Bataille(King's College London), Ricardo Vieira(Hospitais da Universidade de Coimbra), D. Moreno‐Ramírez(Hospital Universitario Virgen Macarena), Célèste Lebbé(Inserm), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Roland Kaufmann(Robert Koch Institute), Catherine Harwood(Queen Mary University of London), Axel Hauschild(University Hospital Schleswig-Holstein), Josep Malvehy(Universitat de Barcelona), Mark R. Middleton(University of Oxford), Claus Garbe(University of Tübingen), Christoph Höeller(Medical University of Vienna), Maria Concetta Fargnoli(University of L'Aquila), Lars Bastholt(Odense University Hospital), V. del Mármol(Université Libre de Bruxelles), Lidija Kandolf Sekulović(Military Medical Academy), M.H.J. van den Beuken-van Everdingen(Maastricht University Medical Centre), Clio Dessinioti(Andreas Sygros Hospital), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Ana‐Maria Forsea(Carol Davila University of Medicine and Pharmacy), Giovanni Pellecani(University of Modena and Reggio Emilia), Ketty Peris(Università Cattolica del Sacro Cuore), Cecille Frenard(Inserm), Alexander M.M. Eggermont(University Medical Center Utrecht), Brigitte Dréno(Nantes Université)
Cited by 324
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k